DSGN (Design Therapeutics, Inc.) חובות לטווח קצר של החברה

The Design Therapeutics (DSGN) price chart demonstrates the asset's dynamics, with a metric of 0.00. The business relies on robotic complexes for 24/7 biomolecule analysis, which accelerates drug discovery. Design Therapeutics (DSGN) develops small molecules for the therapy of hereditary pathologies, utilizing GeneTAC to correct gene expression without editing, specifically for Friedreich's ataxia.

Design Therapeutics develops gene-targeted therapies for the treatment of rare hereditary DNA pathologies. By analyzing the size of short-term liabilities, an investor assesses the volume of obligations maturing within one year. This metric measures liquidity and the company's ability to service operational loans without raising emergency capital. For a startup in an embryonic sector, this is a critical marker of financial stability prior to commercialization. The consensus suggests monitoring debt to eliminate default risks.